TIAA CREF Investment Management’s Dianthus Therapeutics DNTH Stock Holding History

TIAA CREF Investment Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$283K	Buy	+1,072	New	+$185K	﹤0.01%	2793

Other funds holding DNTH

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

TIAA CREF Investment Management's DNTH Position: Q1 2019 in Review

TIAA CREF Investment Management opened a new position in Dianthus Therapeutics (DNTH) in Q1 2019: 1,072 shares worth $283K. The stake represents ﹤0.01% of the portfolio and ranks #2793 among its holdings.

63 funds tracked by Wall St. Rank hold DNTH as of Q1 2019.

TIAA CREF Investment Management held 1,072 shares of Dianthus Therapeutics worth $283K as of Q1 2019.
Dianthus Therapeutics was a new TIAA CREF Investment Management position in Q1 2019.
Dianthus Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2793 holding.
63 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.